The Thromboembolic Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Thromboembolic Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thromboembolic Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thromboembolic Disease and features dormant and discontinued products.
GlobalData tracks six drugs in development for Thromboembolic Disease by six companies/universities/institutes. The top development phase for Thromboembolic Disease is phase i with three drugs in that stage. The Thromboembolic Disease pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Thromboembolic Disease pipeline products market are: University of Queensland, Ionis Pharmaceuticals and Zhejiang Hisun Pharmaceutical.
The key targets in the Thromboembolic Disease pipeline products market include Coagulation Factor XI, Coagulation Factor X, and Coagulation Factor XII.
The key mechanisms of action in the Thromboembolic Disease pipeline product include Coagulation Factor XI Inhibitor with two drugs in Phase I. The Thromboembolic Disease pipeline products include two routes of administration with the top ROA being Oral and four key molecule types in the Thromboembolic Disease pipeline products market including Monoclonal Antibody, and Small Molecule.
Thromboembolic Disease overview
Thromboembolism is a condition in which a a thrombus (blood clot) detaches and blocks the blood vessel (embolizes). Venous thromboembolism can lead to two types of conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk factors that contribute to VTE are injury to vein, infection, immobilization, high estrogen, smoking, obesity, age, chronic illness, and blood clotting conditions. Signs and symptoms include swelling, redness, pain, shortness of breath, tachycardia, tachypnea, and sweating. A thromboembolism is diagnosed by vascular ultrasound, MR venography, contrast venography, pulse oximetry, chest x-ray, and pulmonary angiogram. Treatment options include warfarin, heparin, and low molecular weight heparin (LMWH).
For a complete picture of Thromboembolic Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
